Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232676 | 0.82 | DPP4 (0.50) | DPP4F2CA1CA2CA9 | |
| SCHEMBL13096280 | 0.78 | DPP4 (0.46) | DPP4F2CA1CA2CA9 | |
| SCHEMBL6528197 | 0.78 | DPP4 (0.46) | DPP4F2GBA1SRC | |
| SCHEMBL14642590 | 0.78 | DPP4 (0.46) | DPP4F2CA1CA2CA9 | |
| SCHEMBL332222 | 0.78 | SRC (0.54) | DPP4F2SRC | |
| SCHEMBL2360079 | 0.78 | DPP4 (0.46) | DPP4F2GBA1SRC | |
| SCHEMBL7695092 | 0.77 | CA1 (0.46) | DPP4F2CA1CA2CA9 | |
| SCHEMBL3637962 | 0.77 | CYP2C19 (0.48) | DPP4F2CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL3923326 | 0.76 | DPP4 (0.44) | DPP4F2GBA1 | |
| Hydrochloric Acid SCHEMBL4574710 | 0.76 | DPP4 (0.44) | DPP4F2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022139386-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-06-30 | — | — | WO | claimed |
| EP-3186232-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030852-A1 | P38 MAP KINASE INHIBITING INDANYL UREA COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2016-03-03 | — | — | WO | claimed |
| EP-2748331-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | claimed |
| WO-2013026890-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | claimed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2020-10-22 | — | — | US | disclosed |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2013130943-A1 | ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130943-A1 | ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| EP-0135927-B1 | ANTIHYPERLIPIDEMIC N-BENZOYLSULFAMATES, N-BENZYLSULFAMATES AND BENZYLSULFONAMIDES, A THERAPEUTIC COMPOSITION CONTAINING SAME AND A PROCESS FOR THE PRODUCTION THEREOF | Research Corporation (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0204244-A2 | Tetrakis azo dyes | BAYER AG (DE) | 1986-12-10 | — | — | EP | disclosed |
| EP-0135927-A2 | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides, a therapeutic composition containing same and a process for the production thereof | Research Corporation (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4499303-A | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides | RESEARCH CORPORATION (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | DPP4 2246/4885F2 2927/4885CA1 2182/4885 |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | DPP4 378/4885F2 3283/4885CA1 4406/4885 |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | DPP4 753/4885F2 240/4885CA1 4855/4885 |
| US-20170275278-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | NOS1, NOS2, NOS3 | DPP4 2246/4885F2 2927/4885CA1 2182/4885 |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | DPP4 2246/4885F2 2927/4885CA1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.